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Orthosteric and benzodiazepine cavities of the 122 GABAA receptor: 
Insights from experimentally-validated in silico methods. 
-aminobutyric acid type A (GABAA) receptors mediate fast synaptic inhibition in 
the central nervous system of mammals. They are modulated via several sites by 
numerous compounds, which include GABA, benzodiazepines, ethanol, 
neurosteroids and anaesthetics among others. Due to their potential as targets 
of novel drugs, a detailed knowledge of their structure-function relationships is 
needed. 
Here, we present the model of the α1β22 subtype GABAA receptor in the APO 
state and in complex with selected ligands, including agonists, antagonists and 
allosteric modulators. The model is based on the crystallographic structure of 
the human β3 homopentamer GABAA receptor. The complexes were refined 
using atomistic molecular dynamics simulations. This allowed a broad 
description of the binding modes and the detection of important interactions in 
agreement with experimental information. 
From the best of our knowledge, this is the only model of the α1β22 GABAA 
receptor that represents altogether the desensitized state of the channel and 
comprehensively describes the interactions of ligands of the orthosteric and 
benzodiazepines binding sites in agreement with the available experimental 
data. Furthermore, it is able to explain small differences regarding the binding of 
a variety of chemically divergent ligands. Finally, this new model may pave the 
way for the design of focused experimental studies that will allow a deeper 
description of the receptor. 
Keywords: GABAAR; Benzodiazepines; Homology Modelling; Docking; Molecular 
Dynamics. 
List of Abbreviations 
GABA Gamma-Aminobutyric acid 
GABAARs Gamma-Aminobutyric Acid type A receptors 
CNS Central Nervous System 
ECD Extracellular domain 
TMD Transmembrane domain 
ELIC Erwinia ligand-gated ion channel 
GLIC Gloeobacter ligand-gated ion channel 
AChBP Acetylcholine Binding Protein 
BZDs Benzodiazepines 
i-BZDs Imidazo-Benzodiazepines 
MD Molecular Dynamics 
SCAM Substituted cysteine accessibility method 
POPC 1-palmitoyl-2-oleoyl-phophatidylcholine 
Introduction 
Gamma-Aminobutyric Acid type A receptors (GABAARs) are the main inhibitory 
neurotransmitter receptors in the mammalian central nervous system (Young & Chu, 1990). 
They are members of the Cys-Loop family of Pentameric Ligand Gated Ion Channels (PLGICs), 
along with the cation-selective, excitatory, nicotinic-acetylcholine receptors and serotonin 
receptors; and with the anion-selective, inhibitory, GABAC and Glycine receptors (Ortells & 
Lunt, 1995).  
GABAARs are well characterized as pharmaceutical targets, and thus should be 
exhaustively studied: they have binding sites for a variety of ligands such as GABA, 
benzodiazepines, barbiturates, β-carbolines and neurosteroids among others (Werner 
Sieghart, 1995). In addition, they are involved in a myriad of neurological processes related not 
only to the regulation of inhibition in the CNS but also to the variability of GABAergic signals 
(Rudolph, Crestani, Hanns, & Rudolph, 2001; Vogt, 2015). Their correct functioning is 
extremely important for the health of humans; dysfunctional GABAARs have been related to 
anxiety, sleep disorders, epilepsy, alcohol dependence, among other affections (Collins et al., 
2006; Crestani et al., 1999; Jones-Davis & Macdonald, 2003; Mukherjee, Das, Vaidyanathan, & 
Vasudevan, 2008; Nutt & Malizia, 2001; Yee et al., 2005) .  
GABAA receptors are integral-transmembrane proteins formed by a pseudosymetrical 
arrangement of five subunits, which form a chloride-conducting pore in its centre. There is a 
wealth of GABAA receptor subtypes which display distinct regional, cellular and subcellular 
expression patterns and contribute distinctly to several functions (W Sieghart & Sperk, 2002). 
This diversity is due to the assembly of different combinations of the subunits isoforms; so far 
19 of them are known: 1–6, β1–3, 1–3,,,,, 1–3 (Simon, Wakimoto, Fujita, Lalande, & 
Barnard, 2004). The most abundant isoform in the human CNS is the α1β22 subtype; which, if 
viewed from the extracellular side, displays its subunits sequentially ordered as α1:β2:α1:β2:2 
(anticlockwise)(Figure 1) (Tretter, Ehya, Fuchs, & Sieghart, 1997). 
 
Figure 1. Views of a GABAA receptor depicted with ribbons and coloured according to the 
subunits. 1 in light blue, 2 in tan and 2 in lilac. a. Side view of the receptor. The 
extracellular and transmembrane domains are marked, as well as the loops involved in ligand 
binding. b. Front view of the receptor from the extracellular side;  the binding sites of GABA 
(orthosteric cavity) are indicated with G1 and G2 and the Benzodiazepines high affinity binding 
cavity is indicated with B. The M2 helices are the ones that line the pore. 
 
These receptors are generally divided into three distinct domains (Smith & Olsen, 
1995): the extracellular, the transmembrane and the intracellular. The extracellular domain 
(ECD) is also known as the ligand binding domain because it hosts the orthosteric and 
benzodiazepines binding cavities. It is formed by ten beta strands and two alpha helices. The 
transmembrane domain (TMD), which is formed by four alpha helices, controls the opening 
and closing of the channel pore through the movement of the inner (M2) helices. It also 
contains the binding cavities for other ligands, such as neurosteroids, ethanol and 
anaesthetics. The intracellular (IC) loop has not been completely solved experimentally, 
although it is known to be partially formed by an alpha helix. This domain helps modulate the 
flux of ions and the function of the channel by different mechanisms such as tyrosine 
phosphorylation (Kittler & Moss, 2003; Moss, Gorrie, Amato, & Smart, 1995) and the 
interaction with other proteins.  
In this work, and due to their pharmaceutical relevance, we focused on the 
characterization of the orthosteric and high affinity benzodiazepines binding sites. These 
cavities are homologous and they are located between different pairs of subunits. They are 
both formed by loops A, B and C from the principal subunits and loops D, E and F of the 
respective complementary subunits (Figure 1.a). Different roles have been assigned to these 
loops in the binding of ligands and in allosteric interaction between sites, as well as in 
transmission of the signal in channel gating. Studies of the binding cavities of Cys-loop 
receptors and AChBPs with known structures (Calimet et al., 2013; Puthenkalam et al., 2016) 
have shown that they undergo conformational changes after the binding of the ligands. In 
particular, loop C has been shown to be very mobile, closing itself after agonist binding and 
adopting a more open conformation if the ligand is an antagonist (Puthenkalam et al., 2016). 
These cavities are allosterically and bi-directionally related: modulators that bind to the 
Benzodiazepines cavity modify the conformation of the orthosteric binding sites (Changeux & 
Edelstein, 1998) and it was also demonstrated that the binding of GABA and its activation of 
the receptor cause structural rearrangements in the benzodiazepines site (Teissére & 
Czajkowski, 2001). While the binding of agonists of the benzodiazepines binding site is 
positively coupled to the binding of GABA, imidazo-benzodiazepines are negatively coupled, 
i.e. these modulators stabilize different conformations of the receptor (Teissére & Czajkowski, 
2001). 
There are two orthosteric binding sites, which are located in the ECD between the 
principal face of a -subunit and the complementary face of an -subunit (+/-) (Figure 1.b). 
While site G1 is surrounded by a - and a -subunit, site G2 is flanked by an - and a -subunit. 
Different compounds are known to bind to these cavities; those include the agonist GABA, 
muscimol, bicuculline and gabazine (SR-95531), (Figure 2). On the other hand, the allosteric 
high affinity benzodiazepines’ binding pocket lies between the principal face of an -subunit 
and the complementary face of the -subunit (+/-)(Sigel & Buhr, 1997). The different 
compounds that bind to this site exhibit specific effects and binding affinities. Classic 
benzodiazepines (BZDs), such as diazepam, clonazepam, flurazepam and flunitrazepam, display 
a common 1,4-benzodiazepine nucleus with a 5-phenyl substituent (Sternbach, 1979); imidazo-
benzodiazepines (i-BZDs), such as flumazenil (Ro15-1788) and Ro15-4513, lack the 5-phenyl 
substituent but possess instead an imidazole ring substituted at positions 1 and 2 of the 
diazepine nucleus. Furthermore, there are other non-benzodiazepine ligands of this site, which 
include the imidazopyridine Zolpidem and the cyclopyrrolone Eszopiclone (S-zopiclone) (Figure 
3). 
 
Figure 2. 2D chemical structures of the ligands of the orthosteric cavity employed in this work: 
GABA, Muscimol, Bicuculline and Gabazine. 
 
Figure 3. 2D chemical structures of the allosteric ligands employed in this work. Diazepam, 
Clonazepam, Flunitrazepam, Flurazepam, Ro15-4513, Flumazenil, Zolpidem and Eszopiclone 
bind with high affinity to the allosteric Benzodiazepines site. 
 
Acetylcholine-binding proteins and non-eukaryotic receptors such as ELIC 
(Erwinia ligand-gated ion channel), GLIC (Gloeobacter ligand-gated ion channel) and 
invertebrate Glutamate receptors have been extensively used in the past as templates to 
model mammalian Cys-Loop receptors (Berezhnoy, Gibbs, & Farb, 2009; Bergmann, Kongsbak, 
Sørensen, Sander, & Balle, 2013; Bertaccini, Yoluk, Lindahl, & Trudell, 2013; Carpenter, Lau, & 
Lightstone, 2012; Carpenter & Lightstone, 2016; Cromer, Morton, & Parker, 2002; Ernst, 
Brauchart, Boresch, & Sieghart, 2003; Hénin, Salari, Murlidaran, & Brannigan, 2014; Newell & 
Czajkowski, 2003; Puthenkalam et al., 2016; Sander et al., 2011; Thompson, Lester, & Lummis, 
2010; Xie, Sha, Wang, & Cheng, 2013). However, in 2014 the first 3D structure of a GABAA 
receptor was published by Miller and Aricescu (Miller & Aricescu, 2015). The authors captured 
the spatial disposition of the atoms of a β3 homopentamer, in a desensitized closed state, 
through X-Ray diffraction with a 2.97Å resolution. The desensitized state is proposed to be of 
high affinity for ligands (Zhang, Xue, Liu, Yang, & Wang, 2013). This new structure is not only a 
priceless improvement for the modelling of these receptors, which in turn will provide new 
information to shed light on their structure and functionality, but also constitutes a prototype 
to analyse the binding of pharmacologically relevant compounds (Wang et al., 2017). Over the 
years, different techniques have been used to characterize the binding cavities, providing 
information about the location of the sites and the relevant residues involved directly in the 
interaction or affecting the efficacy of the different ligands. However, the lack of 
crystallographic structures of the 122 heteropentamer hampers the characterization of both 
the specific interactions in the cavity, and the mechanism underlying signal transmission and 
gating. 
Here, using state of the art computational biology tools, we modelled the human 
122 GABAA receptor. Subsequently, we characterized the interactions with the cognate 
ligands by performing docking experiments refined with molecular dynamics (MD) simulations. 
From the best of our knowledge, this is the first model able to widely explain experimental 
data on the aforementioned binding cavities. Indeed, it provides an extensive coverage of the 
relationship between experimental information and structural features of the orthosteric and 
benzodiazepines binding sites.  
Methods 
Constructing the model 
The first step in the comparative modelling protocol consisted in retrieving the sequences of 
the 1, 2 and 2 human subunits from Uniprot (Apweiler et al., 2004; Consortium, 2017): 
entries P14867, P47870 and P18507, respectively. For each subunit we searched for 
homologous sequences with SSearch (Pearson, 1991). The highest scores corresponded to two 
structures: the human GABAA Receptor 3 homopentamer (PDB ID: 4COF) (Miller & Aricescu, 
2015) and human Glycine Receptor 3 homopentamer (PDB ID: 5CFB) (Huang, Chen, 
Michelsen, Schneider, & Shaffer, 2015). Although both of them were captured in the closed 
state, the former was co-crystallised with agonist benzamidine (desensitized state) while the 
latter was co-crystallised with an antagonist (closed-basal state). The differences between 
these structures involve the orientation of the M2 helices and the opening of loop C. The first 
receptor shows the highest percentage of identity with our sequences: approximately 40.8% 
with 1, 91.1% with 2 and 43.2% with 2, while the second shows 41.5% with 1, 45.4% with 
2 and 41.8% with 2. We decided to carry out the modelling using the human 3 GABAA 
Receptor as a template to prioritize a better quality of the sequence alignments. The 
percentages of identity are above the established threshold for confidence in the modelling 
(Table S3 – SI) (Chothia & Lesk, 1986).  
PROMALS (Pei & Grishin, 2007), HHPRED (Söding, Biegert, & Lupas, 2005) and Swiss 
Model (Arnold, Bordoli, Kopp, & Schwede, 2006; Biasini et al., 2014; Kiefer, Arnold, Künzli, 
Bordoli, & Schwede, 2009) were used to generate multiple alignments of the subunits with 
sequences belonging to other family members, and the crystallized homopentamer. The 
results from the three web-servers were compared to find differences only in loop F of 1 
subunit. Manual adjustments of two gaps in loop F of the 1 subunits were applied in order to 
agree with experimental data (as from reference (Bergmann et al., 2013)).Truncation of 
intracellular loops were applied to the alignments following reference (Miller & Aricescu, 
2015). The IC domain was not modelled due to lack of suitable templates. Indeed, this domain 
has not been established as involved in the binding of ligands in the ECD essentially due to the 
long distance between these domains. Naturally, it represents a limit in the implementation of 
the model to observe global conformational changes such as the opening and closing of the 
channel pore.  
500 initial models were generated with Modeller 9.14 (Webb & Sali, 2002) using the 
“Automodel class”, which only includes spatial restraints obtained from the sequence 
alignment of the target and template, and required a refinement level “refine.slow”. The best 
model was determined from the top 20 models, ranked according to the lowest value of the 
Modeller objective function and the “Discrete Optimized Protein Energy” (DOPE) method score 
(Shen & Sali, 2006), as the one showing the largest percentage of residues in the most 
favoured region of the Ramachandran plot. ProSa z-score (Wiederstein & Sippl, 2007),Q-mean 
score (Benkert, Tosatto, & Schomburg, 2008) and PROCHECK (Laskowski, MacArthur, Moss, & 
Thornton, 1993) results were also taken into account in the selection process. These 
evaluation webservers have been extensively applied in several works concerning homology 
modelling (Carpenter et al., 2012; Roy & Mukherjee, 2017). Moreover, the top 20 models were 
carefully visually inspected to detect abnormalities. The chosen model was refined with Coot 
(Emsley, Lohkamp, Scott, & Cowtan, 2010) to optimize rotamers and side chain interactions, 
and PROPKA together with PDB2PQR (Dolinsky, Nielsen, McCammon, & Baker, 2004; Olsson, 
Søndergaard, Rostkowski, & Jensen, 2011; Rostkowski, Olsson, Søndergaard, & Jensen, 2011) 
webserver were employed to assign protonation states and optimize hydrogen bond networks. 
Docking procedures 
In order to find the binding modes of the selected ligands, we conducted a series of molecular 
docking simulations by two methods: blind and data-driven. We used these different 
techniques as a validation for the results when experimental information was not exhaustive 
enough. 
 The blind docking was performed with AutoDock Vina (ADV) (Trott & Olson, 
2010), using a 25 Å x 23 Å x 20 Å grid centred at appropriate coordinates in each binding site. 
All the residues predicted by experimental data to be involved in the binding were within the 
grid-box. We prepared the ligands and the protein with AutoDockTools (Morris et al., 2009) by 
adding missing hydrogens, combining the non-polar hydrogen atoms and computing Gasteiger 
charges. For each ligand a maximum of 20 binding modes were requested and the calculations 
were performed with the highest level of exhaustivity. The cut-off for the number of binding 
modes was a difference in the binding energy of 3 kcal mol between the best and worst 
models. Both simulations with rigid and flexible side chains were performed, showing no 
considerable difference in the results. 
On the other hand, we used HADDOCK 2.2 , High Ambiguity Driven protein-protein 
Docking (Van Zundert et al., 2016), which employs experimental information about the 
interaction to establish the preferred binding modes. The experimental data, when available, 
was introduced as ambiguous interaction restraints (AIR constraints). The docking protocol 
implemented in the software is described elsewhere (Dominguez, Boelens, & Bonvin, 2003). 
The water refined structures were clustered using pairwise backbone Root Mean Square 
Deviation (RMSD) at the interface with a cut-off of 2Å, and analysed according to their average 
interaction energies (the sum of electrostatic, van der Waals and ambiguous restraints 
energies) and their average buried surface area. As stated in HADDOCK webserver, the 
parameterization of the ligands was done with PRODRG (Schüttelkopf & van Aalten, 2004). 
We performed molecular docking simulations with four orthosteric ligands: two 
agonists (GABA and muscimol) and two antagonists (bicuculline and gabazine). The latter were 
studied although the receptor was modelled in an ‘agonist-bound’ state with the aim of 
assessing whether the model is yet adequate for the study of other classes of ligands. 
Following the same premise, we applied this technique to agonists, antagonists and inverse 
agonists of the benzodiazepines binding site; all of which are considerably larger than GABA or 
benzamidine.  
The experimental information (Tables 4 and 5 -SI) used for the data-driven docking of 
each ligand was variable and strongly dependent on the availability. It should be stressed that, 
as implemented in HADDOCK, only a random 50% of these restraints were actually employed 
in the docking simulations. For residues of the orthosteric cavity we used the condition that 
they should interact with 1Arg67, 2Tyr97, 2Glu155, 2Ser156, 2Tyr157, 2Tyr205 and 
2Arg207. However, no particular orientation was introduced as a restraint. As for the 
benzodiazepines binding cavity, the docking of Diazepam had very specific interactions 
incorporated as ambiguous restraints, specifically: the chlorine atom of Diazepam with 
1His102 (Duncalfe, Carpenter, Smillie, Martin, & Dunn, 1996; Tan, Baur, Charon, Goeldner, & 
Sigel, 2009), and C3 of Diazepam with 1Thr207 and 1Ser206 of loop C (Tan et al., 2009). For 
the remaining ligands of the high affinity benzodiazepine’s cavity only, the interacting residues 
were introduced as AIR constraints (Table 1). 
Table 1. List of the residues employed as AIR constraints in the guided docking performed with 
Haddock.  




Ro15-4513 1His102, ,1Tyr210,2Thr81 




The docking poses with the best scores according to both software programs were 
then analysed to compare the modelled interactions between ligand and receptor with those 
extracted from literature. The estimation of the energy of binding provided by the software 
programs was not contrasted with the experimental values due to a lack of direct correlation 
(refer to Table S8 - SI for a discussion on this subject). Contacting atoms were defined as those 
separated by a distance shorter than the sum of their van der Waals radii plus 2.75 Å 
(approximate diameter of a water molecule). Afterwards, we identified through visual 
inspection those atoms that were engaged in biologically relevant interactions (i.e. through H-
bonds, salt-bridges, hydrophobic or cation- interactions, among others). These interactions 
were tabulated and compared with those predicted by experimental studies, and from this 
comparison we computed two indices: Precision and Recall.  These are statistical quantities 
that have been used in other works (Davis & Goadrich, 2006; Fierro, Suku, Alfonso-prieto, & 
Giorgetti, 2017; Goutte & Gaussier, 2005; Raghavan, Bollmann, & Jung, 1989; Saito & 
Rehmsmeier, 2015) to assess the quality of the binding modes resulting from docking 
experiments and to evaluate the performance of the techniques. They are respectively defined 
as: 
                    (1) 
                 (2) 
where TP ‘True Positives’ are residues predicted experimentally as relevant for the binding and 
found in our models to interact with the ligand; FN ‘False Negatives’ are the amino acids 
proposed by the literature to participate in the binding but are not interacting in our models; 
and FP ‘False positives’ are residues identified in our models as interacting with the ligands, 
although experimental data states otherwise, or are those amino acids within a contacting 
distance from the ligand but are not engaged in biological relevant interactions (Figure S1-SI).  
The similarity of ligands might also shed light on their possible orientation inside the 
binding cavity, since it has been proposed that a relationship exists between structural 
similarity and a common binding mode (Boström, Hogner, & Schmitt, 2006). We employed 
OpenBabelGUI, version 2.4.1 (Boyle et al., 2011; Morley, 2016)  to calculate Tanimoto’s 
coefficients to quantify the compounds’ similarity (Figure S4-SI).  
 Molecular dynamics simulations 
Given the static nature of the docking protocols, the performance of molecular dynamics 
simulations would allow the ligands and receptor to adapt to the new conformation of the 
complex. It has been recently shown that in models of protein-ligand interactions of GPCRs, 
based on comparative modelling with low sequence identity, molecular dynamics simulations 
allowed for a better representation of the experimental binding configurations (Fierro et al., 
2017; Gelis, Wolf, Hatt, Neuhaus, & Gerwert, 2012; Lai, Singer, & Crasto, 2005). We 
sequentially simulated the modelled receptor with different docked ligands: one molecule of 
GABA, muscimol, diazepam, clonazepam, flunitrazepam, flurazepam, Ro15-4513, flumazenil, 
eszopiclone and zolpidem.  
The MD simulations were executed with GROMACS (Berendsen, van der Spoel, & van 
Drunen, 1995; Páll, Abraham, Kutzner, Hess, & Lindahl, 2015) using the SPC water model 
(Berendsen, Postma, van Gunsteren, & Hermans, 1981) and the GROMOS53A6 force field 
(Oostenbrink, Villa, Mark, & Van Gunsteren, 2004) for the protein. In all the simulations, the 
receptor, with the ligand attached, was embedded in a pre-equilibrated 1-palmitoyl-2-oleoyl-
phophatidylcholine (POPC) membrane and surrounded by a solution of water and CL-, NA+ 
ions in a concentration of 0.15 Mol. The Berger (Berger, Edholm, & Jähnig, 1997) parameters 
were used to characterize the lipids, and the parameters for the ligands were obtained from 
the Automated Topology Builder repository (Malde et al., 2011). The protocol consisted of an 
energy minimization of the system to a potential energy of 500 k  mol with Steepest Descent 
algorithm, secondly a thermalization in the NPT ensemble with the atom P8 of the 
phospholipids constrained to move on the plane of the membrane using the simulated 
annealing algorithm, then a protein/ligand-position restrained simulation to relax the 
interactions with the solvent, and finally the production runs. Van der Waals interactions were 
limited with a 1.2 nm cut-off and PME algorithm (Darden et al., 1993) was implemented for 
the electrostatic calculations also with 1.2 nm as cut-off. Verlet algorithm (Páll & Hess, 2013) 
was employed for neighbour search, and LINCS constraint algorithm (Hess, Bekker, Berendsen, 
& Fraaije, 1997) was used to restrain bonds’ length. The temperature was kept at 310K with 
Nose-Hoover thermostat (Hoover, 1985; Nosé, 1984) using a coupling constant of tT=0.8ps, 
and the pressure at 1bar with Parrinello-Rahman barostat (Parrinello & Rahman, 1981) and 
using a coupling constant of tT =10ps and compressibility 4.5 10
5bar. All the simulations 
consisted in production runs of 100 ns. 
Results and discussion 
Model construction 
The refined sequence alignment of each human subunit with 3-subunit, which was employed 
for the modelling process, is depicted in Figure 4. The extracellular and transmembrane 
domains consisted in 333 residues for 1 and 332 for 2 and 2. 
Figure 4. Alignment of the human 3 subunit (4COF) with human subunits 1, 2 and 2. The 
sequences numbering corresponds to the proteins in the mature form. The residues are 
coloured according to the percentage of identity with the consensus sequence. Dark blue 
represents an identity of 80% or more, blue corresponds to more than 60%, while light blue 
represents more than 40% identity. The loops that form the binding cavities are underlined in 
green, while the emblematic Cys-loop is underlined in yellow. The intracellular linker is 
underlined in light blue (ICL). 
 
The final model was chosen among the 500 initial configurations by considering 
structural parameters. The results of Q-mean program (Benkert et al., 2008) showed that the 
model is slightly improved, compared to a previous model (Bergmann et al., 2013), and 
acceptable relative to the crystallographic structure (Table S1 – SI). In addition, PROCHECK 
scores were satisfactory (Table S2- SI) and the Ramachandran plot (Figure 5) confirms the good 
quality of the backbone geometry, with 99.8% of the residues in the allowed regions. 
   
Figure 5. Ramachandran plot of the modelled receptor. 94.2% of the residues are in the most 
favoured regions, 5.6% in additional allowed regions and 0.2% in generously allowed regions. 
There are not residues in the disallowed region.   
Molecular Docking 
We performed blind and data-driven molecular docking for ligands of the orthosteric and high 
affinity benzodiazepines’ binding cavity. The results were then statistically compared against 
experimental data available by calculating the recall and precision coefficients. The models 
that better agreed with experimental data were then funnelled through our analysis protocol.   
Orthosteric binding cavity 
 We carried out docking simulations of four orthosteric ligands in both sites G1 and G2 
(Figure 1.b and S3). The results presented here belong to site G1 (except for the docking of 
bicuculline, which belongs to site G2), since the observed binding modes were similar in both 
cavities. In general, all the studies showed very high precision and recall values (Table 2), 
indicating that there are few residues in the binding cavity that cannot be recognized by the 
docking protocols or are not available for interaction in our model. One exception is the 
binding of bicuculline, which shows a better recall value but lower precision. This might be 
caused by the size of this ligand, which occupies a large fraction of the binding cavity in 




Table 2. Precision and recall scores for the performed docking simulations. 
 
Ligand GABA Muscimol Bicuculline Gabazine 
Docking software ADV HADDOCK ADV HADDOCK ADV HADDOCK ADV HADDOCK 
Precision 1.00 1.00 0.85 1.00 0.73 _ 0.93 1.00 
Recall 0.81 0.81 0.79 0.75 0.85 _ 0.72 0.76 
 
 
Figure 6. Best docking poses of the ligands of the orthosteric cavity. The configurations 
displayed correspond to the results with better recall and precision indexes.  a. GABA; b. 
Muscimol; c. Bicuculline; d. Gabazine. 
 
In the best docking mode obtained for GABA (Figure 6.a), the ligand interacts through 
the amine-end with β2Glu155 and through the carboxylic group with 1Arg67, showing 
complete agreement with experimental information. Likewise, the result of the docking of 
muscimol (Figure 6.b) shows hydrogen bonds between the protonated amine with β2Glu155 
and the backbone of β2Ser156 from loop B, and 1Arg67 with the ketone moiety. This mode 
agrees partially with previous models (Bergmann et al., 2013)(Sander et al., 2011). We 
hypothesize that the difficulty in docking bicuculline might be due to the fact that this ligand is 
an antagonist, and therefore it is expected to bind to the cavity with loop C in a more open 
conformation, in contrast to our model, which represents an agonist-bound state of the 
receptor. In our best configuration (Figure 6.c), 1Phe65 lies parallel to the benzene ring of 
bicuculline in a plane 3.6 Å below; they are possibly interacting via - stacking, in agreement 
with experimental data. Being smaller than bicuculline, gabazine is able to fit better inside the 
binding cavity (Figure 6.d). Although the ligand interacts with 1Arg67 and β2Arg207 as 
expected, the experimentally suggested interaction with 1Asp63 is not present in our docking 
poses. Interestingly, bicuculline and gabazine displayed contacts with residues from the -1 
strand, namely 1Phe46, 1Val47 and 1Thr48, which, to our knowledge, have not been 
explored in experimental studies.   
A complete list of the residues involved in interactions with the ligands of the 
orthosteric cavity in the best binding modes obtained through molecular docking is provided in 
Table 3. 
Table 3. List of residues that participate in the interaction with different ligands of the 
orthosteric cavity of GABAARs.  
 
Residues marked with an * are considered false positives. 
 
The docking poses required further refinement since the model considered so far was 
only a static description of the receptor in a particular state. With this aim, we performed 
molecular dynamics simulations of the receptor in complex with GABA, as this is the most 
characterized agonist (Table 4 - SI), and also with muscimol. During the MD simulation, GABA 
relaxed in the binding cavity and formed i) a cation- interaction with an aromatic residue, i.e. 
GABA Muscimol Bicuculline Gabazine 
β2Tyr97 β2Tyr97 β2Tyr97 β2Tyr97 
β2Leu99 β2Leu99 β2Leu99 β2Leu99 
β2Glu155 β2Glu155 β2Glu153* β2Ser156 
β2Ser156 β2Ser156 β2Glu155 β2Tyr157 
β2Tyr157 β2Tyr157 β2Tyr157 β2Phe200 
β2Gly158 β2Gly158 β2Val199* β2Thr202 
β2Phe200 β2Phe200 β2Phe200 β2Tyr205 
β2Thr202 β2Tyr205 β2Thr202 β2Arg207 
β2Tyr205 1Phe65 β2Tyr205 1Phe46 
1Phe65 1Arg67 β2Arg207 1Thr48 
1Arg67 1Leu118 1Phe65 1Phe65 
1Leu118  1Arg67 1Arg67 
  1Leu118 1Leu118 
  1Arg120* 1Thr130 
  1Thr130 1Val181 
  1Val180*  
  1Val181  
2Phe200, ii) H-bonds with the tip of loop C, while maintaining the salt-bridges with 2Glu155 
and 1Arg67 (Figure S9–SI). The network of interactions with this compound was refined in 
such a way that precision remained in its maximum value, but the recall value improved (Table 
S6-SI). In addition, it can be appreciated that loop C opened slightly and loop F approached the 
principal subunit through residue 1Asp184, which came close to 2Arg207 (Figure S19– SI). In 
particular, residue 1Asp184 has drawn our attention, since it has been proposed as important 
in GABA binding, although, as it is located in loop F, it is far from the core of the binding site. 
However, this residue appeared in the docking results of Gabazine, the competitive antagonist, 
and it is observed that, while GABA remains bound, 1Asp184 moved towards the principal 
face of the cavity in molecular dynamics simulations. 
2Glu153 and 2Lys196 form a putative salt-bridge that regulates the movements of 
loop C during activation (Venkatachalan & Czajkowski, 2008). This interaction is supposed to 
be disrupted upon agonists binding and the consequent conformational change of loop C. In 
our initial model and throughout the MD simulation, although spatially close (~7 Å), these 
residues could not form a salt-bridge, which is consistent with the ligand-bound state of the 
template structure (Venkatachalan & Czajkowski, 2008). Moreover, in the cavity where GABA 
is bound, 2Glu153 is part of a stable interacting network which includes 2Glu155 and 
2Arg207. On the other site, the MD simulation showed a change in the interactions, in which 
2Glu155 now interacts with 1Arg120 and 2Arg207 (Figures S20 and S21 –SI). This change in 
the interaction pattern might be related to the transmission of the agonist signalling. 
The MD simulation of muscimol improved both scores to their maximum value (Table 
S6-SI). The ligand remained in the cavity exploring alternate conformations with orientations 
that differed in rotations around the main axis of the molecule, engaging in several H-bonds 
with 2Ser156, 2Tyr97, 1Thr130, 2Thr202 and 1Arg120 (Figure S10–SI). The compound 
spent most of the simulation in a conformation similar to the starting pose.  
Benzodiazepines binding cavity 
Classical benzodiazepines share, among them, high similarity in their physico-chemical 
properties. These positive allosteric modulators are expected to bind near residues 2Ala79 
and 1His102, in particular the pharmacophore model derived from in vitro experiments 
(Clayton et al., 2007), suggested that the 7-substitutent of classical benzodiazepines should be 
located between residues Val203, Val212 and Tyr210 from loop C and His102 of loop A 
(Duncalfe et al., 1996) (Figure S5 – SI).  
Table 4. Recall and precision indices of the docking results of ligands of the high affinity 
benzodiazepines binding cavity on the GABAA receptor.  
Ligand Diazepam Clonazepam 
Flunitrazepa
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The best result for the docking of diazepam (Figure 7.a) displays its chlorine atom 
pointing towards 1His102, 1Asn103 and 2Asn60 and the C3 atom in the vicinity of the tip of 
loop C. In addition, the phenyl ring is surrounded by a hydrophobic cavity formed by 
1Phe100, 2Phe77, 1Tyr160 and 1Tyr210. As proposed in literature, the N-methyl 
substituent points outside the binding cavity (Tan et al., 2009) and the benzodiazepine ring lies 
above 2Tyr58 in a parallel plane. Both precision and recall indices are high. Moreover, this 
configuration agrees well with those proposed by previous works (Berezhnoy et al., 2009; 
Middendorp et al., 2014) and with experimental information (Clayton et al., 2007, Table 5 -SI). 
We compared this docking pose with those reported by Richter et al. (2012), finding our model 
resembles their second ranked mode, since it places the pending phenyl ring inside the 
lipophilic cavity in the back of the binding site, in contrast to their best binding pose which 
orients the ring outwards. The rest of the classic benzodiazepines also display high values of 
both precision and recall (Table 4). For these ligands, except Flunitrazepam (Figure 7.c), the 
pending phenyl ring is surrounded by the characteristic hydrophobic cavity. Flunitrazepam’s 7-
substituent (a fluorine atom) interacts with 1His102 and 2Tyr58, which cannot be completely 
fulfilled by flurazepam (Figure 7.d), whose chlorine atom only interacts with 2Tyr58 or by 
clonazepam (Figure 7.b), which locates the nitro group above 2Tyr58 and ~7Å from 1His102. 
Remarkably, most of the interactions in the cavity are hydrophobic, which might account for 
the high values of the indices. Most of the residues involved in the binding of these ligands 
(Table 5) are the same as the ones suggested in the literature (Table S5 - SI). 
Bearing in mind the information available regarding the binding of diazepam, we 
performed two MD simulations, starting with the best configurations obtained from both 
docking methods. Throughout the simulations, Diazepam changed its orientation to adopt an 
almost identical configuration in the binding cavity for both MD simulations; the precision and 
recall scores exhibited small differences due to alternative disposition of the surrounding side 
chains. However, the final refined model showed improved indices (Tables S6 and S7 - SI). On 
the other hand, along the MD simulations of clonazepam, this ligand sampled different 
conformations within the cavity so that the benzodiazepine ring lays parallel to the membrane 
plane, the nitro group points outside the cavity and the chloro-phenyl ring remains in the 
hydrophobic cavity. During the simulation with flunitrazepam the side-chains of surrounding 
residues relaxed in the cavity, while the ligand remained virtually motionless, improving 
slightly both evaluation parameters. The second best docking pose obtained for flurazepam 
(Figure 7.d), although it shows lower precision and recall scores, resembles the pose adopted 
by bromoflurazepam while interacting with the prokaryotic receptor ELIC (Spurny et al., 2012) 
in one of its crystallographic structures (PDB ID: 4A98). Thus, we used this configuration to 
perform the MD simulations. Along the simulations, the ligand undergoes several changes in 
its orientation to finally converge to a conformation resembling the starting pose. 
 
Figure 7. Best docking modes of the classic BZDs. a. Diazepam, b. Clonazepam, c. 
Flunitrazepam, d. Flurazepam. 
 
Regarding the imidazo-benzodiazepines (i-BZD), while they show high similarity 
between them, they are very different compared to classical benzodiazepines (Figure S4 –SI). 
Mutation and SCAM studies have shown that the 3’ substituent of the i-BZD’s imidazo-ring is 
located nearby 2Ala79 and 2Thr81 (Kucken, Teissére, Seffinga-clark, Wagner, & Czajkowski, 
2003), and the 7-substituent should be pointing towards 1His102, 1Val203, 1Val212 and 
1Gly158 from loop B (Tan et al., 2007). 1Tyr210 is proposed to photoincorporate Ro15-4513, 
with the azide group pointing towards that region (Sawyer, Chiara, Olsen, & Cohen, 2002).  The 
best docking configurations of Ro15-4513 (Figure 8.a) and flumazenil (Figure 8.b) have their 
imidazo 3’-substituent pointing towards 2Ala79 and the 7-substituent pointing towards 
1His102. Additionally, 1Tyr210 interacts directly with Ro15-4513. Both models are in 
agreement with the requirements of the pharmarcophore model (Clayton et al., 2007). 
However, there are discrepancies regarding the orientation of the 4th and 5th positions of the 
benzodiazepine ring: these atoms point into the interior of the binding cavity in some of our 
models, but in one of the bests configurations obtained for Ro15-4513 the imidazole ring is 
orientated inwards, while these atoms point outwards. Previous models have oriented these 
atoms to the exterior of the cavity (Kucken et al., 2003) similar to the behaviour of the N-
methyl and carbonyl moieties in Diazepam. 
Since the binding modes for Ro15-4513 show identical scores (Table 4), we performed 
MD simulations for both systems. The model with the imidazole ring pointing inwards 
displayed better results: The simulation improved the precision and recall scores (Table 6), and 
the ligand adopted a stable configuration with loop C in an open conformation. Regarding the 
binding mode of flumazenil, MD simulations were not able to improve the docking precision 
and recall values. In our docking studies the best binding modes differed in the orientation of 
the imidazole ring. Considering that the MD simulations of Ro15-4513 gave better results for 
the system with the ligand oriented so that the imidazole ring points into the cavity, we 
believe that binding mode of flumazenil should also reproduce this feature. 
 
Figure 8. Best docking modes of the i-BZDs according to precision and recall scores. a. Ro15-
4513, b. Flumazenil. 
 
The docking studies of zolpidem resulted in very similar conformations which 
displayed comparable recall and precision indexes (Table 4). The observed interactions are 
mostly hydrophobic (Table 5). It has been already proposed that, since it does not share many 
polar interactions, the binding mode of zolpidem depends more on the shape of the cavity 
rather than on the interaction with particular residues (Hanson, Morlock, Satyshur, & 
Czajkowski, 2008). The best configuration (Figure 9.a) can be related to previous 
computational studies performed with a different model (Vijayan, Bhattacharyya, & Ghoshal, 
2012) and with the pharmacophore model based on experimental information (Clayton et al., 
2007). However, in our model there is no direct interaction between the ligand and loop F as 
proposed in literature (Table 5 – SI). 
Concerning the docking of eszopiclone (Figure 9.b), the best binding mode possesses 
high indices of precision and recall (Table 4) and agrees well with the pharmacophore model 
based on experimental data (Clayton et al., 2007). In addition, the orientation is similar to the 
one adopted by R-zopiclone bound to ELIC receptor (Spurny et al., 2012) (PDB ID: 4A97). Both 
ligands share common interactions with conserved aromatic residues (Table 5), even though 
the spatial disposition of the side-chains is not exactly preserved. The chlorine atom is oriented 
towards the back of the cavity, between 1Tyr160 and 1Tyr210 and the methyl-piperazine 
group is located near 1His102 and 1Phe100, while the pyridine ring interacts with 2Phe77 
and 1Thr206. The pyrrolo-pyrazin is located under the tip of loop C and above 2Tyr58. The 
free carboxyl interacts with 2Tyr58 through and H-bond. A docking mode similar to that 
proposed by Hanson et al. (Hanson et al., 2008) was also found with ADV with the same 
binding score. 
Both ligands remained bound during the MD simulations, with eszopiclone temporarily 
exploring other conformations along its simulation while zolpidem retained its orientation. 
Even though precision was increased for both ligands, recall was somewhat reduced (Table 6). 
 
Figure 9. Best docking modes of two of the non-benzodiazepine compounds that bind to the 








Table 5. List of residues that participate on the interaction with ligands of the high affinity 





































































































































2Leu140 2Thr142 2Tyr58 2Tyr58 2Ala79 2Tyr58 2Phe77 
2Thr14
2 
2Thr142  2Phe77 2Phe77 
2Met13
0 
2Phe77 2Ala 79 
2Gly19
1 

















      2Thr142  
Residues marked with an * were considered false positives. 
There are certain residues suggested in literature (Table 5 -SI) as relevant in the 
binding of ligands but which are not observed in any of our models to have an active 
interaction with the compounds. For instance, residue 1Gly201 is located at the base of loop 
C; its mutation probably affects the binding of the ligands (zolpidem and eszopiclone) because 
longer chains might alter the movement capacity of this loop. This mutation might also modify 
the orientation of the neighbouring side-chains and directly affect the entrance of the ligand  
(Hanson et al., 2008). Regarding the hypothetical interaction of flunitrazepam and zolpidem 
with 2Met57, from our models we suggest that it may be very difficult for the side chain of 
this residue to interact directly with the ligands, because it is located in a beta strand with the 
side chain oriented outwards in the cavity. In addition, considering the following residue is 
2Tyr58, which has also been proved to directly interact with ligand, the disposition of the 
amino acids in the secondary structure seems correct. On the other hand, the experimentally 
observed reduction of binding affinities when 1Gly158 or 1Gly208 are mutated to Cys (Table 
5 – SI), can be explained by our model since a mutation in these positions would severely 
reduce the available volume of the cavity and alter the interactions between residues. The 
mutation 1G158C makes it possible for Ro15-4513 to interact with this residue through its 
azide moiety, as suggested experimentally (Tan et al., 2007). 
Essentially, the refinement MD simulations performed on the receptor in complex with 
the allosteric modulators, improved both recall and precision indices (Tables S6 and S7 - SI). All 
of the ligands remained bound to the cavity within the 100ns of simulation and most of them 
did not change their orientation drastically (Figures S11-S18 –SI). Flurazepam and diazepam 
displayed the most noticeable movements. The stability of the complexes and the ligands 
within the binding cavity was ascertained through measurements of the root-mean-square 




































MD ADV MD 
Precisio 0.8 1.0 0.92 0.88 0.92 0.93 0.87 0.94 0.8 0.9 0.93 0.7 0.88 
1.0 0.93 1 


















As a final remark, this work could provide a starting point for the design of several 
experimental studies. On the one hand, confirmation of the binding modes for the ligands is 
needed. On the other hand, we observed potential interactions between the ligands and 
unexplored regions of the receptor such as the amino acids from the -1 strand in the 
orthosteric binding pocket, thus, we propose that mutational and substituted-cysteine 
accessibility method (SCAM) analysis would contribute greatly to understand the participation 
of these residues, which have been proposed to participate in the binding process in analogy 
with the benzodiazepines’ binding site (Kucken et al., 2000). The approach of loop F of the 
orthosteric cavity towards the principal face through 1Asp184 in the MD simulations is a hint 
on the mechanisms involving this loop. Thus we propose cross-linking and mutational studies 
should be performed on this residue in order to asses its role in the binding and activation of 
the channel, and the allosteric influence of benzodiazepines. 
Conclusions 
Due to their role in neurological health and vast pharmacology, the study of the structure of 
GABAA receptors, their function and interactions with other molecules is essential to 
understand the bases of many diseases and develop new treatments, as well as strategies for 
improving life quality.   
It was not until 2014 that the first crystallographic structure of a GABAA receptor was 
published. For this reason, previous models were performed with templates sharing very low 
sequence identity belonging to other receptors of the Cys-loop family and AChBPs. In this 
work, we present a model of the α1β22 GABAA receptor in a closed-desensitized state based on 
the human β3 homopentamer (Figure S2 – SI). The model here presented is able to reproduce 
active binding cavities, as they have been validated against all the existing experimental data.  
Due to the lack of a heteromeric structure in the apo-state or with bound ligands, 
state-of-the-art computational studies can be combined with experimental data to obtain 
information about the binding and conformational changes in the receptor that lead to its 
opening and closing. Docking results, although sometimes ambiguous, allowed us to propose 
binding modes for different ligands and helped in the formulation of hypotheses about the 
important residues. In this work, the docking procedures were able to capture the main 
features of the interaction of the receptor and its cognate ligands. Refinement using MD 
simulations allowed us to improve the results by providing a more extensive sampling of the 
conformational space of the ligand interacting with the receptor. 
Regarding the binding properties of ligands of the orthosteric cavity, agonists GABA 
and muscimol could be docked in conformations that are similar for both compounds, in 
agreement with previous works (Bergmann et al., 2013; Boileau, Evers, Davis, & Czajkowski, 
1999; Goldschen-Ohm, Wagner, & Jones, 2011; Holden & Czajkowski, 2002; Newell, McDevitt, 
& Czajkowski, 2004; Sander et al., 2011). Bicuculline, however, could not be located in a 
precise configuration in this model of the receptor, probably due to its size and the fact that it 
is an antagonist, and therefore it is expected to bind in the cavity with loop C in an open 
conformation. While gabazine, being smaller, fitted well into the cavity and was engaged in 
several of the suggested interactions (Boileau et al., 1999; Newell et al., 2004; Padgett, Hanek, 
Lester, Dougherty, & Lummis, 2007; Wagner & Czajkowski, 2001; Westh-Hansen et al., 1999) 
(Table 4 of the SI). 
The current information about the high affinity benzodiazepines binding cavity allowed 
us to propose a binding mode for diazepam which is able to explain the available experimental 
data (Clayton et al., 2007;Hanson & Czajkowski, 2008; Middendorp et al., 2014; Tan et al., 
2009, Table S5-SI). Other classical benzodiazepines, namely clonazepam, flunitrazepam and 
flurazepam, were docked in modes that are compatible with experimental data but which do 
not share exactly the same binding features as diazepam. The imidazo-benzodiazepines could 
also be docked based on experimental information (Kucken et al., 2003; Middendorp et al., 
2014; Morlock & Czajkowski, 2011), showing that this site, in our model, is capable of binding 
not only positive modulators, but also antagonists and negative modulators. Non-
benzodiazepine drugs zolpidem and eszopiclone exhibited binding modes that are also in 
agreement with experimental data (Hanson et al., 2008). Remarkably, the docking of 
eszopiclone could be directly compared to the crystallographic structure of R-zopiclone bound 
to a prokariotic homologue receptor (ELIC) (Spurny et al., 2012). Both ligands show high 
similarity in the orientation within the cavity and make common key contacts with 
homologous hydrophobic residues of the binding sites. 
In conclusion, we built a model of the 122 GABAA receptor, comprising both the 
extracellular and transmembrane domains, which was then docked with compounds of the 
orthosteric and benzodiazepines binding sites. All the described complexes are in agreement 
with the available experimental data. We therefore suggest that this model can be used in 
future studies related to the orthosteric and benzodiazepines binding sites. Additionally, we 
propose that mutational and SCAM analysis would contribute greatly to understand the 
participation of amino acids from the -1 strand in the orthosteric cavity. Finally, we consider 
that this model might contribute to the future development of novel strategies for the design 
of specific orthosteric/allosteric ligands.  
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Supplementary information - Orthosteric and benzodiazepine cavities of 
the 122 GABAA receptor: Insights from experimentally-validated in 
silico methods. 
Methods 
The Recall and Precision coefficients are defined as relations between True Positives (TP), False 
Positives (FP) and False Negatives (FN).  
 
Figure S1. Scheme representing the classification of the interactions between the ligands and 
the receptor. Rcut-off is defined in this work as 2.75Å. 
Analysis of the model  
Table S1. Qmean and z-scores obtained for the model, the crystallized structure and a previous 
model (Bergmann, Kongsbak, Sørensen, Sander, & Balle, 2013) showing that the structure of 











Table S2. G-factors of stereochemical parameters analysed with Procheck also show that our 
modelled receptor maintains an overall good structure. Procheck calculates these values based 
on an analysis of 163 non-homologous, high-resolution protein chains selected from structures 











From visual inspection, the chosen model represents correctly both the secondary and tertiary 
structure of the receptor. The root mean square deviation (RMSD) was calculated for each 
chain with respect to the crystallographic structure of the template, resulting in an average of 
0.15  0.03 Å.  
In addition, we measured with HOLE software (Smart, Neduvelil, Wang, Wallace, & 
Sansom, 1996) the pore profile along the z axis. The analysis of the central pore (Fig. 5) showed 
that there is a constriction of 1.5 Å delimited by the M2 helices residues 1Pro240, β2Ala239 
and 2Pro239. With this radius no chloride ions can permeate through the channel (ros~4 Å) 
confirming that our modelled structure is in a closed state (Miller & Aricescu, 2015).  
Structure Qmean score Z-score 
Our model 0.572 -2.11 
4COF 0.581 -2.04 
Previous model 0.507 -2.88 
Parameter G-factor 
Phi-psi distribution 0.11 
Chi1-Chi2 0.22 
Chi1 only 0.34 
Chi3 and Chi4 0.54 
Omega -0.13 
Overall average 0.03 
 
Figure S2. The channel shows a constriction on the lower part of the transmembrane domain, 
which is in agreement with a desensitized state, in contraposition to an inactive-closed state 
that displays the constriction in the upper region of the TMD (Hilf & Dutzler, 2008; Miller & 
Aricescu, 2015; Unwin, 2005). 
Employing homology models in molecular docking simulations 
It has been subject of debate whether homology models are adequate to be employed in 
molecular docking studies (both of proteins and small ligands). For data-driven docking 
experiments, the global folding and the reliability on the information used to guide the docking 
are the most important aspects for obtaining good predictions (Rodrigues et al., 2013). When 
the docking is not guided by experiment, it has been shown that the sequence identity, in 
particular the local sequence identity, is highly correlated with the quality of the docking 
results (Bordogna, Pandini, & Bonati, 2011); therefore, we calculated the sequence identity for 
the six loops involved in the binding cavities. 
Table S3. Local sequence identity between the template (PDB ID: 4COF) and the α1, β2 and 2 
subunits. 
Loop 1 2 2 
Loop A  60%* 100%** 60% 
Loop B 50%* 100%** 62.5% 
Loop C 33%* 66%** 25% 
Loop D 40%** 80% 40%* 
Loop E 46%** 100% 53.8%* 
Loop F 30%** 77% 22%* 
*Loops involved in the benzodiazepines binding cavity 
**Loops involved in the orthosteric binding cavity. 
Even though loop F of the 2 subunit has low (30%) sequence similarity, it does not 
contain gaps in the alignment. The other loops involved in the binding show at least 30% of 
sequence identity with the template, giving more confidence to the docking results. These 
differences in the primary structure are consistent with a specificity of the compounds that 
bind to each binding site. 
Orthosteric binding site. 
 
Figure S3. Stereoscopic view of the orthosteric cavity. Amino acids which have been found to 
form the binding site are represented by lines: those that are in the core of the site according 
to our model are highlighted in colour khaki, while the ones lining the cavity are in light blue. 
Table S4. Experimentally-suggested interactions between ligands and residues of the 
orthosteric binding cavity. 
Loop Residue Role Source 
A 
2Y97 
 Cation- interaction with GABA 
 SCAM studies show that it is part of the 
binding site. 
 Its mutation reduces the sensitivity towards 
GABA and gabazine. 
(Boileau, Newell, & 
Czajkowski, 2002; Padgett, 
Hanek, Lester, Dougherty, 
& Lummis, 2007) 
2L99 
 SCAM studies show it is part of the binding 
site, although it might not interact directly 
with GABA. 
(Boileau et al., 2002) 
B 2E155 
 Its mutation affects channel gating and 
weakens the binding of agonists. 
(Newell, McDevitt, & 
Czajkowski, 2004) 
 Interaction with the amino group of GABA 
(in sílico model). 
2S156 
 Hypothetic H-bond with GABA. 
 Its mutation reduces the sensitivity towards 
GABA and gabazine. 
(Newell et al., 2004) 
2Y157 
 It is not proposed to interact via cation-, 
but through its hydroxyl group. 
 Its mutation decreases apparent 
affinity/sensitivity of GABA and muscimol. 
Might interact with the carboxyl-like 3-
isoxazole moiety of muscimol. 
 When mutated to Serine, bicuculline and 
gabazine act as partial agonists. 
(Amin & Weiss, 1993; 
Padgett et al., 2007) 
2G158 
 Mutation reduces the affinity for GABA and 
gabazine. 
(Newell et al., 2004) 
2T160 
 Its mutation decreases apparent 
affinity/sensitivity of GABA and muscimol. 
 SCAM studies show it is part of the binding 
site and participates in channel gating. 
(Amin & Weiss, 1993; 
Newell et al., 2004) 
2D163 
 SCAM studies show it is part of the binding 
site and participates in channel gating. 
(Newell et al., 2004) 
C 
2F200 
 Its mutation affects the binding of gabazine 
and GABA, and the activation of the 
channel. 




 Its mutation reduces the sensitivity towards 
GABA and gabazine. 
(Wagner & Czajkowski, 
2001) 
2T202 
 Its mutation deactivates the channel. 
 Its mutation decreases apparent 
affinity/sensitivity of GABA and muscimol. 
 Its mutation reduces the sensitivity towards 
GABA and gabazine. 
(Amin & Weiss, 1993; 
Wagner & Czajkowski, 
2001) 
2G203 
 Its mutation reduces the sensitivity towards 
GABA and gabazine. 




 SCAM studies show it lines and faces into 
the binding site. Its mutation did not affect 
binding affinity of either GABA or gabazine. 




 Its mutation decreases apparent 
affinity/sensitivity of GABA, muscimol, 
bicuculline and gabazine.  
(Amin & Weiss, 1993; 
Padgett et al., 2007; 
Wagner & Czajkowski, 
 SCAM studies show it lines and faces into 
the binding site. 
2001) 
2R207 
 Mutation causes a decrease in GABA and 
agonists binding, but not gabazine. 
 Proposed to stabilize the antagonists 
binding. 
 Not involved in the gating process. 
 SCAM studies show it lines and faces into 
the binding site. 
(Goldschen-Ohm, Wagner, 
& Jones, 2011; Wagner & 
Czajkowski, 2001; Wagner, 
Czajkowski, & Jones, 2004) 
2S209 
 SCAM studies show it lines and faces into 
the binding site. It did not affect binding 
affinity of either GABA or gabazine. 







 SCAM studies show that gabazine protects 
this residue, but not GABA. 
(Boileau, Evers, Davis, & 
Czajkowski, 1999) 
1F65 
 Identified as part of the binding site by 
SCAM studies. 
 Photoaffinity labelling of this residue shows 
that it reacts with the carboxylate-like part 
of muscimol. 
 Mutation studies show decreased binding 
affinity for agonists and antagonists (GABA, 
bicuculline, gabazine). 
(Boileau et al., 1999; 
Holden & Czajkowski, 2002; 
Sigel, Baur, Kellenberger, & 
Malherbe, 1992), (Smith & 
Olsen, 1994) 
1R67 
 Forms part of the binding cavity 
(Photoaffinity labelling, SCAM). 
 It is conserved in all GABAA receptor ,  
and  subunits. 
 Proposed as the anchor of the carboxyl 
group of GABA. 
 Its mutation causes a decrease in the 
binding of GABA and other agonists. 
 Proposed to obstruct the binding of 
antagonists. 
 It is not involved in the gating process. 
(Boileau et al., 1999; 
Goldschen-Ohm et al., 
2011; Holden & Czajkowski, 
2002) 
1S69 
 Identified as part of the binding site by 
SCAM studies. 
(Boileau et al., 1999; 
Holden & Czajkowski, 2002) 
E 
1N116 
 SCAM studies predict it lines the binding 
site. 
(Kloda & Czajkowski, 2007) 
1L118 
 SCAM studies predict it lines the binding 
site. 
(Kloda & Czajkowski, 2007) 
1R120  SCAM studies predict it lines the binding (Kloda & Czajkowski, 2007; 
site. 
 Its mutation reduces the binding affinity of 
muscimol and gabazine, and produces a loss 
in sensitivity to GABA. 
S. E. Westh-Hansen et al., 
1999)  
1I121 
 SCAM studies predict it lines the binding 
site. 
 Its mutation reduces the sensitivity to GABA 
and muscimol, but not bicuculline. 
(Svend Erik Westh-Hansen 
et al., 1997) 
1T130 
 SCAM studies predict it lines the binding 
site. 
(Kloda & Czajkowski, 2007) 
1R132 
 SCAM studies predict it lines the binding 
site. 
 Its mutation causes a decrease in GABA 
binding. 
 Proposed to stabilize the binding of 
antagonists. 
 Involved in the gating process. 
(Goldschen-Ohm et al., 
2011; Kloda & Czajkowski, 
2007; Wagner et al., 2004)  
F 
1V179 
 SCAM studies show it is part of the binding 
site, although it might not interact directly 
with GABA. 
(Newell & Czajkowski, 
2003) 
1V181 
 SCAM studies show it is part of the binding 
site, although it might not interact directly 
with GABA. 
(Newell & Czajkowski, 
2003) 
1D184 
 SCAM studies show it is part of the binding 
site, although it might not interact directly 
with GABA. 
(Newell & Czajkowski, 
2003) 
SCAM: substituted cysteine accessibility method. 
It is important to note, that relevant residues from the orthosteric site have their 
analogues in the high affinity benzodiazepines binding site; for example 2Tyr157 and 
1Tyr159, 2Tyr205 and 1Tyr209. 
High affinity benzodiazepines binding cavity 
We calculated the Tanimoto coefficients for the ligands of the high affinity benzodiazepines 
binding site. This coefficient can be related to resemblance in binding and function. Such 
coefficient is defined as: TC A,B  
c
a b-c
. Where c is the number of features A and B share, and a 
and b are the number of features present in each compound (Maggiora, Vogt, Stumpfe, & 
Bajorath, 2014). This coefficient is considered one of the best metrics for similarity calculation. 
Classical benzodiazepines share high similarity, which is reflected in the high Tanimoto 
indexes between them. On the other hand, imidazo-benzodiazepines show high similarity 
between them, but very low compared to classical benzodiazepines, confirming there is a 
substantial difference between these molecules and their expected binding modes. Despite 
being agonists, Zolpidem and Eszopiclone display very low Tanimoto indexes, which are 
expected because of the prominent different geometry. 
 Figure S4. Tanimoto coefficient for the ligands of the benzodiazepines binding site 
employed in this work. 
 
Figure S5. Stereoscopic view of the high affinity benzodiazepine binding cavity. Residues that 
have been identified as part of the binding site are depicted with licorice: in colour khaki those 
that form the core of the site and in light blue those that, according to our model, only line the 
cavity. 
Table S5: Summary of the experimental information concerning the amino acids that are 
putatively involved in the interaction with ligands, or that are an important part of the binding 
site.  
Loop Residue Role Source 
A 
1D98 
 Mutation studies have shown it affects both 
the binding and efficacy of agonists, as well 




Morlock & Czajkowski, 
2011) 
1F100 
 Mutations studies have shown it affects both 
binding and efficacy of agonists. 
 Involved in - stacking. 
 Its mutation to cysteine, switches the action 
of eszopiclone and diazepam from positive 
allosteric modulators to negative modulators, 
but it does not affect the binding of 
flumazenil. It reduces the binding affinity of 
zolpidem and eszopiclone. 
 It has been proposed that, if mutated, this 
amino acid can interfere with the spatial 
disposition of the side chains of 1His102 and 
1Tyr160. 
(Hanson et al., 2008; 
Morlock & Czajkowski, 
2011; Tan, Baur, 




 SCAM studies have shown that the chlorine 
atom of diazepam points towards this 
residue. 
 It is photolabelled by flunitrazepam. 
 Identified through domain exchange and site-
directed mutagenesis as necessary for the 
binding of diazepam and zolpidem. 
 Its mutation to arginine decreases the 
binding of flumazenil but does not affect 
Ro15-4513 (i-BDZs bind to receptors formed 
by 4 and 6 subunits). 
 Its mutation decreases the binding affinity of 
zopiclone. (The reduction is smallest if 
mutated to phenylalanine). 
 The 7-substituent of i-BDZs is nearby this 
residue. (Proximity-accelerated chemical 
coupling) 
 Mutations to arginine cause Ro15-4531 and 
flumazenil to turn into potent positive 
modulators (altering efficacy). While making 
the receptors insensitive to diazepam 
(altering affinity). 
(Benson, Löw, Keist, 
Mohler, & Rudolph, 
1998; Berezhnoy, 
Nyfeler, Gonthier, 
Goeldner, & Sigel, 
2004; Davies, Newell, 
Derry, Martin, & Dunn, 
2000; Duncalfe, 
Carpenter, Smillie, 
Martin, & Dunn, 1996; 
Middendorp et al., 
2014; Tan, Gonthier, et 
al., 2007; Tan, Baur, 
Charon, Goeldner, & 
Sigel, 2009; Wieland & 
Lüddens, 1994; 





 Studies by proximity-accelerated chemical 
coupling reaction showed it points into the 
binding pocket. 
 It is expected that the chlorine atom of 
diazepam and 7-substituent of i-BDZs point 
towards this residue, but it is less accessible 
than His102. 
 Its mutation to cysteine does not affect the 
binding of flumazenil. 
(Tan et al., 2009; Tan, 
Baur, et al., 2007) 
B 
1G158 
 Mutations studies have shown it affects both 
binding and efficacy of agonists. 
 The chlorine atom of diazepam points 
towards this residue. 
 The 7-substituent of i-BDZs is nearby this 
residue. (Proximity-accelerated chemical 
coupling). 
 Its mutation to cysteine reduces the binding 
affinity of Zolpidem and Eszopiclone. 
(Hanson et al., 2008; 
Morlock & Czajkowski, 
2011; Tan, Gonthier, et 
al., 2007; Tan et al., 
2009) 
1S159 
 Its mutation to cysteine decreased the 
binding affinity of flunitrazepam and 
flumazenil. 
(Tan, Gonthier, et al., 
2007; Tan et al., 2009) 
1Y160 
 SCAM studies have shown that it lines the 
binding cavity. 
 Replacement by serine resulted in the loss of 
flumazenil and diazepam binding. 
 Its mutation to cysteine decreased the 
binding affinity of flunitrazepam and 
flumazenil. 
[17](Amin et al., 1997; 
Tan, Gonthier, et al., 
2007; Tan et al., 2009) 
1T163 
 Mutation studies have shown that it is 
important for the binding affinity of 
diazepam. 
 Its mutation to alanine causes an increase in 
efficiency of diazepam and zolpidem, and a 
negligibly increase in the sensitivity of 
diazepam. 
(Buhr, Baur, Malherbe, 
& Sigel, 1996; Wieland 
& Lüddens, 1994) 
C 
1G201 
 Its mutation to cysteine causes a reduction of 
the binding affinities of flurazepam, 
eszopiclone and zolpidem. 
 If mutated to glutamic acid, the affinity of 
zolpidem is reduced, while the affinity of 
flumazenil is increased and that of diazepam 
does not change. 
(Hanson et al., 2008; 
Morlock & Czajkowski, 
2011; Pritchett & 
Seeburg, 1991; 
Schaerer, Buhr, Baur, & 
Sigel, 1998; Wieland & 
Lüddens, 1994) 
1V203 
 The chlorine atom of diazepam points 
towards this residue. 
 The 7-substituent of i-BDZs is nearby this 
residue. (Proximity-accelerated chemical 
coupling) 
 Its mutation to cysteine reduces the binding 
affinity of zolpidem and eszopiclone. 
(Hanson et al., 2008; 
Tan, Gonthier, et al., 
2007) 
1S205  Its mutation affects the binding affinity of 
zolpidem. 
(Hanson et al., 2008) 
1S206 
 It has been experimentally (proximity-
accelerated Chemical coupling) related to C3 
atom from the benzodiazepine ring. 
 Its mutation to alanine does not affect the 
potentiation of classical benzodiazepines. 
 Its mutation to asparagine causes a decrease 
(Buhr et al., 1996; 
Derry, Dunn, & Davies, 
2004; Middendorp et 
al., 2014; Tan et al., 
2009) 




 It is related to the efficacy of flurazepam, 
eszopiclone and zolpidem but not to their 
binding affinity. 
 It has been experimentally (proximity-
accelerated chemical coupling) related to C3 
atom from the benzodiazepine ring. 
 It shares polar contacts with the group N-
methyl, which is directed outside the cavity. 
 Mutation to alanine shows a small decrease 
in the affinity of flumazenil, diazepam and 
zolpidem. It also causes an increase in 
efficiency of diazepam and zolpidem. 
 Its mutation to valine causes a decrease in 
the binding affinity of diazepam and 
zolpidem, and an increase of the binding 
affinity of flumazenil.  
(Buhr et al., 1996; 
Buhr, Schaerer, et al., 
1997; Morlock & 
Czajkowski, 2011; 
Schaerer et al., 1998; 
Sigel, Schaerer, Buhr, & 
Baur, 1998; Tan et al., 
2009) 
1G208 
 Its mutation to cysteine decreases the 
binding affinity of flunitrazepam and 
flumazenil. 
(Tan, Gonthier, et al., 
2007; Tan et al., 2009) 
1Y210 
 Mutations studies have shown it affects both 
binding and efficacy of agonists. 
 The aromatic feature is important for the 
binding of ligands. 
 Its mutation to glutamine or cysteine 
abolished the binding affinity for flumazenil 
and flunitrazepam. 
 Replacement by phenylalanine causes a 
reduction of the binding of flumazenil, 
diazepam and zolpidem, while replacement 
by serine or alanine an abolition of the 
binding of these ligands.  
 Ro15-4513 is photo-incorporated into this 
residue; it is proposed to react with the azide 
group. 
(Amin et al., 1997; 
Buhr, Schaerer, et al., 
1997; Hanson et al., 
2008; Morlock & 
Czajkowski, 2011), 
(Sawyer, Chiara, Olsen, 
& Cohen, 2002) 
1V212 
 When mutated to cysteine it increases the 
efficacy of zolpidem. 
 The chlorine atom of diazepam points 
towards this residue. 
 The 7-substituent of i-BDZs is nearby this 
residue. (Proximity-accelerated chemical 
coupling) 
 Mutation studies have shown that it is 
important for flunitrazepam and diazepam, 
but Ro15-4513 prefers an isoleucine in this 
position. 
(Morlock & Czajkowski, 
2011; Tan, Gonthier, et 
al., 2007; Tan et al., 
2009; Wieland & 
Lüddens, 1994) 





 Mutation studies have shown it is essential 
for the high-affinity binding of flunitrazepam. 
 It has been identified as important for the 
binding of zolpidem. 
(Buhr & Sigel, 1997; 
Kucken et al., 2000) 
 
2Y58 
 Mutation studies have shown it is essential 
for the high-affinity binding of flunitrazepam. 
 Its mutation to cysteine causes a decrease in 
the binding affinity of flunitrazepam and 
diazepam, but not flumazenil. 
 Through proximity-accelerated chemical 
coupling reaction, it has been related to C3 
atom in the benzodiazepine ring and the 7 
substituent. 
(Kucken et al., 2000; 




 Its mutation to cysteine causes a slight 
decrease in the binding affinity of 
flunitrazepam and diazepam, but not 
flumazenil. 
 Through proximity-accelerated chemical 
coupling reaction, it has been related the 7 
substituent of classical benzodiazepines. 




 Its mutation to cysteine severely affects the 
binding of flunitrazepam and abolishes the 
binding of flumazenil. 




 It is essential for functioning and the binding 
of flumazenil and clonazepam. 
 Its mutation to isoleucine resulted in a 
complete loss of the affinities of zolpidem 
and flumazenil, while high affinity to 
flunitrazepam was retained. 
 Its mutation to cysteine resulted in a 
complete loss of potentiation by flurazepam, 
zolpidem, flunitrazepam and flumazenil. 
 Its mutation to leucine resulted in a complete 
loss of potentiation and binding of zolpidem, 
while affinity to diazepam and flumazenil was 
retained but reduced. 
 Its mutation to tyrosine considerably reduced 
the binding affinity of diazepam and 
flunitrazepam, but slightly increased the 
affinity of zolpidem and had no effect on 
flumazenil. 
 Its mutation to tryptophan reduced 
considerably the binding affinities of 
flumazenil and diazepam. 
(Buhr et al., 1996; 
Buhr, Baur, & Sigel, 
1997; Sigel et al., 1998; 
Tan et al., 2009; 
Teissére & Czajkowski, 
2001; Wingrove, 
Thompson, Wafford, & 
Whiting, 1997) 
2A79 
 Mutation studies have shown it is important 
for high-affinity binding of classic 
benzodiazepines. 
 Its mutation to cysteine reduces the binding 
(Hanson et al., 2008; 
Kucken et al., 2000; 
Kucken, Teissére, 
Seffinga-clark, Wagner, 
affinity of zolpidem and eszopiclone. 
 Fundamental for the high affinity binding of i-
BDZs. SCAM studies showed the 
3’substituent of the i-BDZs lies near this 
residue. 
 SCAM studies revealed that it lies within the 
BZDs binding site. 
 Its mutation to a tyrosine affected the 
binding of i-BDZs, but not of flunitrazepam. 
& Czajkowski, 2003; 
Teissére & Czajkowski, 
2001) 
2T81 
 Its mutation affects the binding of i-BDZs and 
classical BDZs to a less extent. 
 Its mutation to cysteine reduces the binding 
affinity of zolpidem. 
 SCAM studies revealed that it lies within the 
BZD binding site, it is located near the 
3’substituent of i-BDZs and flurazepam does 
not protect it from covalent modification. 
(Hanson et al., 2008; 
Kucken et al., 2000, 




 Its mutation to cysteine causes a reduction of 
the binding affinities of flurazepam, 
eszopiclone and zolpidem. Other studies 
show this mutation increases the binding 
affinity of zolpidem. 
 The mutation to leucine leads to a 51-fold 
loss in the affinity for zolpidem while affinity 
for diazepam is only slightly reduced. 
 Mutational studies show it does not affect 
the binding of flumazenil, but determines the 
binding of flunitrazepam and clonazepam. 
(Buhr & Sigel, 1997; 
Hanson et al., 2008; 
Morlock & Czajkowski, 
2011; Sigel et al., 1998; 
Wingrove et al., 1997) 
2R132 
 Its mutation to cysteine causes a reduction of 
the binding affinities of flurazepam, 
eszopiclone and zolpidem. 
 Other studies show this mutation increases 
the binding affinity of zolpidem. 
(Hanson et al., 2008; 
Morlock & Czajkowski, 
2011) 
2T142 
 Its mutation to serine causes Ro15-4513 and 
flumazenil to turn into potent positive 
modulators. Further potentiation of GABA 
responses by diazepam, clonazepam, or 
flunitrazepam doubled in receptors 
containing this mutation. In contrast, 
responses to zolpidem were roughly halved. 
 
 
(Mihic, Whiting, Klein, 
Wafford, & Harris, 
1994) 
2R144 
 When mutated to cysteine, it reduced the 
binding affinity of eszopiclone. 
(Hanson et al., 2008) 
2E189 
 When mutated to cysteine, it increased the 
efficacy of zolpidem. 
(Morlock & Czajkowski, 
2011) 
F 2V190 
 Although it is not directly in contact with 
diazepam, it is associated with the 
orientation of the ligand. 
 Through proximity-accelerated chemical 
coupling reaction it was shown that classical 
(Middendorp et al., 
2014) 
 
benzodiazepines orient their NCH3 group 
towards this residue. 
2R197 
 It is related to the efficacy of flurazepam, 
eszopiclone and zopidem but not to their 
binding affinity. 
 Flurazepam and zolpidem significantly slowed 
its covalent modification, suggesting 
movements in loop F, after binding. 
(Hanson & Czajkowski, 
2008; Morlock & 
Czajkowski, 2011) 
 
Stability of the MD Simulations 
We evaluated the root-mean-square deviation (RMSD) of the different complexes throughout 
the MD simulations and compared their values to the one obtained for the crystallographic 
structure under the same conditions. All the systems are stable after approximately 60ns and 
the RSMD never exeeds 0.5 nm.  
 
Figure S7. C-RMSD plot for the complexes formed by the receptor and the different ligands 
along the molecular dynamics simulations.   
 
In addition, with the aim of assessing the global movements of the ligands inside the 
binding cavity we calculated RMSD of the ligands with respect to the initial conformation 
(Figure S8). Fitting procedures were applied, to rotation and translation, on the protein. The 
results should highlight the stability of the ligands, a property that has been related to the 
reliability and accuracy of the predicted complexes (Alonso, Bliznyuk, & Gready, 2006). 
Flurazempam as well as diazepam display the largest RMSD values due to an initial drastic 
change in conformation and a subsequent stability, which can be appreciated through the 
visualization of the trajectory. This initial reorientation might be related to slightly lower values 
of Recall in comparison with the other ligands. Although they can be considered high, the false 
positive contacts might account for repulsive forces that lead to the observed movements. The 
rest of the compounds suffer less changes in their position and orientation inside the cavity 
and the RMSD values can be related to small movements due to the relaxation of the side 
chains of the surrounding residues. 
 
Figure S8. RMSD of the ligands with respect to their initial conformation along the molecular 
dynamics simulations.   
Binding modes obtained from the MD simulations 
The binding modes of GABA and muscimol obtained from the MD simulations are depicted in 
Figures 9 and 10. 
As a general feature, the binding poses of the ligands of the orthosteric cavity were 
improved throughout the MD simulations provided the recall and precision values are 
considered. Those amino acids involved in the interaction with the ligands were classified as 
True Positives, False Positives and False Negatives according to the criteria explained in the 
methods section. 
 Whereas the binding poses of ligands that were examined through MD simulations do 
not present False Positive residues, those that have yet to be refined, display a few number of 
bad contacts due to their large size and lack of reorganization of the side-chains of the 
surrounding amino acids. Regarding the false negatives for GABA, β2Ser156 is observed to 
form an H-bond with the ligand momentarily and therefore cannot be considered as a true 
positive, although longer simulations might statistically improve the contact. β2R207 is 
engaged in an interaction with a residue from loop F (Figure 19) and interacts with β2Glu155 
(Figure 21), thus, even though it is not interacting directly with the ligand it has an active 
participation in the binding mode. 
Table 6. Categorization of residues according to their interaction with the ligands of the 
orthosteric cavity.  
Ligand True Positives False Positives False Negatives 
GABA 
β2Tyr97, β2Glu155, β2Tyr157, β2Gly158, 
β2Phe200, β2Ser201, β2Thr202, 






β2Tyr97, β2Glu155, β2Ser156, β2Tyr157,  
β2Phe200, β2Thr202, β2Tyr205, 




β2Tyr97, β2Leu99,  β2Tyr157,  
β2Phe200, β2Thr202, β2Tyr205, 









β2Tyr97, β2Leu99, β2Ser156, β2Tyr157,  
β2Phe200, β2Thr202, β2Gly203, 
β2Tyr205, 1Phe65, 1Arg67, 






† The results here presented for these ligands are obtained from the molecular docking.  
 
Figure S9. Representation of GABA bound to the model of the GABAA receptor. The image 
corresponds to the representative frame after clustering the trajectory obtained from the 
100ns MD simulation. 
 
Figure S10. Muscimol is depicted bound to the modelled receptor as in the middle frame of the 
clustering of the trajectory obtained from their MD simulation. 
 
Regarding the binding poses of the ligands in the benzodiazepines high affinity binding site, we 
observed that the recall and precision scores were generally increased, except in the 
simulation of flumazenil. The residues involved in the putative interactions are categorised in 
Table 7.  
 While the binding mode of diazepam does not present false positives, 1Thr207 and 
2Ala79 appear far from the ligand; the first due to the opening of the tip of loop C, the latter 
because of the rearrangement in the orientation of diazepam. However, the interaction of the 
classical benzodiazepines with 2Ala79 is not clear. 
The binding mode of clonazepam exhibits a false positive since 2Asn60 interacts with 
the ligand but is not engaged in a natural occurring interaction. Conversely, 1Ser159 
constitutes a false negative since in analogy to the binding of flunitrazepam it should interact 
with the ligand. 
Due to the opening of loop C, 1Thr207 is not engaged in the predicted interaction 
with flunitrazepam, while 2Ala79 and 2Ser61 belong to the binding site, but afar from this 
ligand.  
The binding mode of flurazepam obtained from MD simulations displays 2Arg132 
within the range of interaction of the ligand but is not engaged in any naturally occurring 
interaction. On the other hand 1Gly201, 2Ala79, 2Met130 are all far from the ligand.  
Regarding the amino acids experimentally involved in the binding of Ro15-4513, 
2Thr81 lies in the model far from the binding site. However, this ligand shows an interaction 
with 2Arg97 in the pose obtained by MD simulations, which is not experimentally predicted to 
interact with the ligand. The abundance of bad contacts of flumazenil has been related to an 
initial bad conformation. 
Neither zolpidem nor eszopiclone exhibit false positives. However, both display two 
false negatives: 2Thr81, 2Met130 for the former and, 2Arg132 and 2Arg144 for the latter. 
The absence of contact with 2Met130 is mainly due to the movement of the ligand inside the 
cavity and the relaxation of the side chains of the surrounding amino acids, since it was initially 
involved in the binding. As has been observed for previous ligands 2Thr81 is not modelled 
inside the binding site in our receptor. 2Arg132 and 2Arg144 lie in the upper and lower sides 
of the cavity respectively; they are engaged in other interactions but are not close enough to 
the ligand to interact with it. Mutating these ligands to a cysteine might cause changes in the 








Table 7. Classification of residues according to their interaction with the ligands of the 
benzodiazepines binding cavity. 
Ligand True Positives False Positives False Negatives 
Diazepam 
1Phe100, 1His102, 1Asn103, 
1Tyr160, 1Val203, 1Ser206, 
1Tyr210, 1Val212, 2Tyr58, 





1Phe100, 1His102, 1Gly158, 
1Tyr160, 1Val203, 1Ser206, 
1Thr207, 1Gly208, 1Tyr210, 
1Val212, 2Tyr 58, 2Phe77, 
2Ala79, 2Met130, 2Thr142 
2Asn60 1Ser159 
Flunitrazepam 
1Phe100, 1His102, 1Ser159, 
1Tyr160, 1Val203, 1Ser205, 
1Tyr210, 1Val212, 2Tyr 58, 
2Asn60, 2Phe77, 2Met130, 
2Arg132, 2Thr142 
1Thr207, 2Ala79, 2Ser61 
Flurazepam 
1Phe100, 1His102, 1Ser159, 
1Tyr160, 1Val203, 1Ser205, 
1Thr207 1Tyr210, 1Val212, 2Tyr 






1Phe100, 1His102, 1Gly158, 
1Ser159, 1Tyr160, 1Val203, 
1Ser205, 1Ser206,  1Thr207 
1Tyr210, 1Val212, 2Tyr58, 




1His102, 1Tyr160, 1Val203, 
1Ser205, 1Thr207 1Tyr210, 










1Phe100, 1His102, 1Gly158, 
1Ser159, 1Tyr160, 1Val203, 
1Ser206,  1Thr207 1Tyr210, 






1Phe100, 1His102, 1Gly158, 
1Ser159, 1Tyr160, 1Val203, 
1Ser206,  1Tyr210, 1Val212, 








Figure S11. Diazepam bound to the model of the GABAA receptor taken from the middle frame 




Figure S12. Representative frame of the trajectory of the MD simulation of clonazepam bound 
to the modelled receptor. 
 
Figure S13. Flunitrazepam is depicted while bound to the modelled receptor in the middle 
frame of the clustering of the trajectory of the MD simulation. 
 
Figure S14. Flurazepam bound to the model of the GABAA receptor taken from the middle 
frame after clustering of the 100ns MD simulation.  
 
Figure S15. Ro154513 bound to the model of the GABAA receptor taken from the middle frame 
after clustering of the 100ns MD simulation. 
 
Figure S16. Flumazenil is depicted while bound to the modelled receptor in the middle frame 
of the clustering of the MD simulation. 
 
Figure S17. Zolpidem is depicted while bound to the modelled receptor in the middle frame of 
the clustering of the MD simulation. 
 
 
Figure S18. Eszopiclone is depicted while bound to the modelled receptor in the middle frame 
of the clustering of the MD simulation. 
Behaviour observed in the simulations of GABA bound to GABAAR. 
It is interesting to highlight the behaviour, during the MD simulations of the holo-receptor with 
GABA bound, of certain residues, such as 1Asp184, 1Arg120, 2Arg207, 2Glu153 and 
2Glu155. 
 
Figure S19. During the MD simulation of the receptor with a bound GABA molecule, we 
observed that Loop F approaches the principal face of the binding site. It is represented here 
as the distance between Asp184 of the aforementioned loop and Arg207 from loop C in the 
presence and absence of GABA.  
Figure S20. Interaction patterns for 1Arg120 and 2Glu155. The absence of GABA stabilizes 
the interaction between these two residues.  
Figure S21. The interaction network of Glu153, Glu155 and Arg207 from the 2 subunits does 
not display such noticeable differences in the presence/absence of GABA. 
Interplay between experimental data and in silico predictions.  
A drawback in contrasting experimental data with docking results lies in the fact that generally 
the former does not give accurate information about the actual interaction between the 
ligands and the amino acids. Through mutational studies, photolabelling, cysteine substitution 
methods, etc., amino acids which are somehow involved in the interaction or are part of the 
binding cavity can be detected. However this does not necessarily mean they are directly 
interacting with the compounds; they can instead have an active role in preserving the shape 
of the binding cavity or they might be forming networks of interactions with contacting 
residues and therefore mediating local conformational movements. Within this uncertainty we 
predicted the binding modes for the chosen ligands, knowing that in several circumstances 
different orientations are possible within the binding cavity. In this regard, it has been 
proposed for PLGICs that the ligands might act as a wedge between residues in the binding site 
initiating the allosteric transmission of the signal, without engaging in precise interactions (Mu, 
Lester, & Dougherty, 2003).  
Conventionally, docking protocols exhibit a weakness regarding the correct estimation 
of the binding affinities since the values are highly dependent on the scoring function 
employed (Kitchen, Decornez, Furr, & Bajorath, 2004; Lenselink et al., 2016; Olsson, García-
Sosa, & Ryde, 2018). As a matter of fact, the software programs employed in this work offer 
different ways of calculating the probability of the binding pose. HADDOCK, for instance, does 
not deliver a value for energy of binding, but calculates and classifies the structures according 
to the HADDOCK score (Kastritis & Bonvin, 2010), which cannot be directly correlated to the 
energy of the binding. Moreover, although AutoDock Vina gives an energy value estimation, it 
is not directly comparable to experimental binding energies either (Ramírez & Caballero, 2016; 
Trott & Olson, 2010). We compared the energy of binding according to AutodockVina for the 
ligands of the orthosteric cavity to those measured experimentally (Table S8) and saw no 
correlation or trend in the results, consistently with the above cited references. 
Table S8. The comparison of the values for the binding energy of different compounds of the 
orthosteric cavity constitutes a clear example of the limitation of the docking programs to 
correctly evaluate this function. 
Ligand 
Experimental Ki [nmol] (Svend Erik Westh-
Hansen et al., 1997) 
Experimental G 
[kcal/mol]† 




11,0 -10,9 -5,6 
GABA 56,0 -9,9 -4,8 
Gabazi
ne 
10,0 -10,9 -8,1 
Bicucul
line 
7300,0 -7,0 -10,2 
† Calculated using the equation    
   
    
Other computational approaches exist which attempt to estimate the free energy of 
binding, such as Free Energy Perturbation, Linear Interaction Energy and MM-PBSA. However, 
these are very computationally expensive and in some cases are not accurate enough (Chipot, 
2013; Gaieb et al., 2018).  
 Bearing this limitation in mind, we employed a different methodology for evaluating 
the docking poses; we contrasted the best binding modes according to each software against 
experimental information regarding the interactions with surrounding amino acids. This 
evaluation method has been successfully applied in similar works (Fierro, Suku, Alfonso-prieto, 
& Giorgetti, 2017; Sandal et al., 2015).   
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